25 Oct 2019 --- Start-up Pepticom, which uses artificial intelligence (AI) to accelerate peptide drug discovery, has secured US$5 million in Series A funding from the Chartered Group. The investment will facilitate the development of new AI models to further increase molecular discovery efficacy, while reducing the risk for the next stages of development. As well as being used in agriculture, the technology can help address problems ranging from metabolic and autoimmune disease to oncology.
